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Introduction
Inflammation is a key contributor to many disease processes. 
Whereas ligand-receptor systems regulating microbial-induced 
inflammation have been characterized in detail in the past 2 
decades, the molecular regulation of sterile inflammation remains 
poorly understood. Sterile inflammation typically occurs in 
response to cell death (1) and often leads to detrimental exacer-
bation of the initial insult. It has been proposed that endogenous 
molecules released from dying cells, termed damage-associ-
ated molecular patterns (DAMPs), exert an essential role in this 
danger response (1–5). However, the role of specific DAMPs in 
disease processes in vivo and the mechanisms through which 
they regulate sterile inflammation remain ill-defined. Defining 
DAMPs that trigger sterile inflammation in response to cell death 
is of high relevance, as excessive inflammation often results in 
collateral damage and contributes significantly to morbidity and 
mortality (6). Accordingly, pharmacologic targeting of DAMPs 
may be of substantial therapeutic benefit — across organs — in 
settings that involve significant tissue injury. A large number of 
candidates including heat-shock proteins (HSPs), mitochondrial 
DNA, hyaluronan, formyl peptides, ATP, uric acid, S100B, and 
high–mobility group box 1 (HMGB1) have been suggested to act as 
DAMPs (5, 7), but only a few of these molecules have a confirmed 
DAMP function in vivo. As such, HSPs were once considered key 
proinflammatory DAMPs, but have recently been suggested to 
dampen immune responses (8). Likewise, HMGB1 has been sug-
gested to amplify inflammation rather than directly triggering it 
(9–11). Much of the uncertainty about the role of DAMPs in sterile 
inflammation arises from a lack of clean genetic approaches that 
allow assessment of the contribution of single DAMPs to relevant 
disease settings in vivo. As such, there are virtually no mouse 
models in which candidate DAMPs have been knocked out. At the 
same time, most DAMP receptors (for which knockouts exist) are 
promiscuous and recognize multiple endogenous and bacterial 
ligands, making it difficult to sort out the contribution of specific 
DAMPs to relevant disease processes.
HMGB1 is a key DAMP candidate with proposed functions 
in the regulation of inflammation following tissue injury, LPS- 
induced shock, and UV irradiation (3, 4, 12, 13). In the healthy 
organism, HMGB1 functions as a DNA-binding protein that, 
without apparent sequence specificity, induces bends in the DNA 
helix, allowing interactions between DNA and proteins such as 
p53, NF-κB, homeobox-containing proteins, recombinases, and 
steroid hormone receptors (14). Although mice with global Hmgb1 
deletion die shortly after birth (15), several recent studies have 
shown that intracellular HMGB1 is not required for cell homeo-
stasis and organ function in the healthy adult organism (16–18). 
During tissue injury or sepsis, HMGB1 is passively released from 
necrotic cells and actively secreted by inflammatory cells, with 
signature posttranslational modifications that are characteristic of 
the respective release mechanism (19). In addition, the oxidation 
status of critical cysteine residues, which is largely determined by 
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an inducible and highly efficient strategy to delete Hmgb1 from 
IFN-responsive cells (30), we achieved complete inhibition of the 
LPS-induced increase in serum HMGB1 at early and late time points 
(Figure 1A) as well as almost complete loss of HMGB1 expression in 
the liver, bone marrow (BM), and macrophages (Supplemental Fig-
ure 1, A–C; full uncut gels are shown in the Supplemental material). 
Despite this efficient reduction of LPS-induced serum HMGB1, 
we observed no influence on LPS-induced inflammatory gene 
expression or cytokine secretion and even observed a trend toward 
slightly increased mortality (Figure 1, B–D), in contrast therefore 
with results from previous antibody-based studies demonstrating 
that HMGB1 neutralization was protective against LPS-induced 
death (13, 31). These data were further confirmed by crossing Vav1-
Cre–transgenic mice, which display Cre-mediated recombination 
in hematopoietic cells (32), with Hmgb1fl/fl (Hmgb1ΔBM) mice, result-
ing in almost complete loss of HMGB1 expression levels in BM, 
spleen, and F4/80-positive hepatic macrophages, but no signifi-
cant reduction in overall HMGB1 levels in the liver (Supplemen-
tal Figure 1, D and E). Deletion in endothelial cells, as previously 
reported for a different Vav1-Cre–transgenic mouse (33), occurred 
only in a minority of endothelial cells in several tested organs 
including the liver (20.9% ± 0.9%), kidneys (21.1% ± 9.2%), and 
heart (23.0% ± 3.0%) (Supplemental Figure 1, E and F). As with 
Mx1-Cre–mediated deletion, Vav1-Cre–mediated Hmgb1 deletion 
resulted in significantly reduced levels of circulating HMGB1 (Fig-
ure 1E), but did not significantly affect LPS-induced lethality at 2 
different LPS doses (Figure 1, F and G). Taken together, these data 
suggest that HMGB1 does not constitute a key mediator of LPS- 
induced inflammation or lethal shock. Based on these findings, we 
investigated the hypothesis that HMGB1 operates as a regulator of 
inflammation in settings other than LPS-induced shock.
HMGB1 promotes neutrophil but not macrophage migration 
toward necrotic tissue. In addition to active secretion from inflam-
matory cells, e.g., after stimulation with LPS, HMGB1 is also pas-
sively released from necrotic cells, consistent with the concept of 
a proinflammatory DAMP. We therefore tested the role of HMGB1 
in host responses to injury using necrotic tissue from Hmgb1- 
deleted or Hmgb1fl/fl control mice. Neutrophils, the first respond-
ers to tissue injury, displayed a greater than 7-fold increase in 
migration toward Hmgb1fl/fl tissue lysates. Of note, Hmgb1 deletion 
almost completely mitigated the ability of tissue lysates to induce 
neutrophil migration (Figure 2A). In contrast to neutrophils, mac-
rophage migration was not affected by Hmgb1 deletion of tissue 
lysates (Figure 2A). We made similar observations in vivo, where 
inflammatory cell infiltration was reduced after i.p. injection of 
Hmgb1-deleted liver lysates compared with injection of Hmgb1fl/fl 
lysates (Figure 2A). In summary, these data indicate that HMGB1 
may be a key DAMP that triggers the migration of neutrophils but 
not macrophages toward necrotic tissue.
HMGB1 promotes neutrophil migration and injury amplifica-
tion after necrosis in vivo. To test the DAMP function of epithelial 
HMGB1 in vivo and its role in linking necrosis to neutrophil-medi-
ated inflammatory responses in clinically relevant disease models, 
we subjected mice with an albumin-Cre–driven hepatocyte-spe-
cific Hmgb1 knockout (Hmgb1Δhep) to ischemia and reperfusion (I/R) 
injury. Of note, this hepatic epithelial–knockout mouse shows a 
virtually complete absence of HMGB1 in HNF4α-positive hepato-
the physicochemical properties of the wound microenvironment, 
modulates the biological effects of extracellular HMGB1 (20). 
Thus, the function of the molecule is believed to be highly con-
text dependent. It has been suggested that extracellular HMGB1 
is a key mediator of sterile inflammation after necrosis and of 
LPS-induced lethality (13). Similar to many other DAMPs, the role 
of HMGB1 as a relevant promoter of inflammation and disease 
processes remains controversial: (a) the early postnatal lethality of 
Hmgb1-knockout mice (15) has precluded studying HMGB1 func-
tions and its contributions to disease processes in vivo by genetic 
approaches; (b) HMGB1 has been suggested to act as an amplifier 
of TLR-dependent inflammation rather than a primary trigger of 
inflammation. In particular, contaminating DAMPs have been 
suggested to be responsible for proinflammatory effects of recom-
binant HMGB1, thus challenging its function as a true DAMP (10, 
11). To date, virtually all functions of HMGB1 have been assessed 
using pharmacologic HMGB1 inhibition, recombinant HMGB1, or 
cell lines. Of note, previous septic shock studies, in which HMGB1 
was shown to mediate lethality (13), have demonstrated major dif-
ferences between experimental approaches using TNF- and IL-1–
neutralizing antibodies, which prevented LPS-induced lethality 
(21–24), and genetic approaches, in which TNF-, TNFR-, and 
IL-1R–deficient mice displayed normal sensitivity to LPS-induced 
septic shock (25–27). Subsequent clinical studies that spanned 
more than a decade did not find clear benefits of TNF neutraliza-
tion (28), and this approach has subsequently been abandoned as 
a therapeutic strategy in septic shock. These findings emphasize 
the importance of genetic approaches in understanding the con-
tribution of inflammatory mediators to disease processes such as 
septic shock and tissue injury.
Here, we studied the role of HMGB1 in sterile and LPS- 
induced inflammation using conditional HMGB1 ablation in a 
recently generated transgenic mouse (16). We demonstrate that 
HMGB1 exerts an essential role in recruiting neutrophils to sites 
of necrotic tissue injury, resulting in sterile inflammation, injury 
amplification, and decreased survival. Surprisingly, HMGB1 
did not promote inflammation or death in LPS-induced shock. 
Together, these data implicate HMGB1 as a potential therapeutic 
target in the setting of tissue necrosis to interrupt the HMGB1-trig-
gered amplification loop that follows organ injury.
Results
HMGB1 does not mediate LPS-induced lethal shock. One of the 
most striking functions of extracellular HMGB1 in the regulation 
of inflammation has been demonstrated in LPS-mediated septic 
shock, an often lethal syndrome that affects 750,000 patients 
annually in the US alone and accounts for 10% of all ICU admis-
sions (29). A previous study demonstrated that HMGB1 acts as a 
late mediator of LPS-mediated shock, with a neutralizing HMGB1 
antibody increasing survival rates in LPS-treated mice from 0% to 
70% (13). To study the contribution of HMGB1 to LPS-mediated 
shock, we used conditional ablation of HMGB1 using a recently 
generated transgenic mouse (16). This well-characterized mouse 
model does not display altered gene transcription, cellular homeo-
stasis, or organ function after Hmgb1 deletion in adulthood (16), 
making it ideally suited to investigate HMGB1 contributions 
to inflammatory disease processes in vivo. Using Mx1-Cre as 
Downloaded from http://www.jci.org on February 13, 2015.   http://dx.doi.org/10.1172/JCI76887
The Journal of Clinical Investigation   R e s e a R c h  a R t i c l e
5 4 1jci.org   Volume 125   Number 2   February 2015
proinflammatory gene expression in Hmgb1Δhep mice (Figure 3, C 
and D, and Supplemental Figure 3B). Consistent with our in vitro 
findings and observation in the I/R model, Hmgb1 deletion selec-
tively affected neutrophil infiltration without altering the number 
of hepatic macrophages (Figure 3, E and F). Alterations in neu-
trophil recruitment and inflammation could not be attributed to 
differences in the metabolic activation of acetaminophen, a pre-
requisite for its toxicity, or to hepatocyte sensitivity to acetamin-
ophen, since acetaminophen adducts, early hepatic GSH deple-
tion, and Cyp2e1 expression (Supplemental Figure 3, C–F), as well 
as acetaminophen-induced death of primary hepatocytes (Figure 
3B) were similar in Hmgb1fl/fl and Hmgb1Δhep mice. Since neutrophil 
infiltration preceded differences in chemokine expression between 
Hmgb1fl/fl and Hmgb1Δhep mice (Supplemental Figure 4A), the effects 
of HMGB1 on neutrophils appeared not to be directly caused by 
HMGB1-mediated modulation of chemokine expression. Accord-
ingly, we found that neutrophil recruitment toward necrotic liver 
tissue was not altered by pharmacologic inhibition of CXCL2 or its 
receptor CXCR4 by neutralizing antibodies or AMD3100, respec-
tively (Supplemental Figure 4B). Hence, the differences in chemo-
kine levels between Hmgb1fl/fl and Hmgb1Δhep mice we observed at 
later time points were likely a consequence of different levels of 
neutrophil-mediated inflammation and liver injury. It is conceiv-
able that these differences in chemokine expression additionally 
contribute to differences in neutrophil accumulation between 
Hmgb1fl/fl and Hmgb1Δhep mice at later stages. At later time points, we 
found that the decreased neutrophil infiltration in Hmgb1Δhep mice 
translated into attenuated liver injury, with striking reductions in 
serum ALT and AST (Figure 3G) and liver necrosis (Figure 3H). Of 
note, 100% of Hmgb1Δhep mice survived a lethal dose of acetamin-
cytes and cytokeratin-positive biliary epithelial cells, but preserves 
HMGB1 expression in other hepatic cell populations including 
F4/80-positive macrophages, CD31-positive endothelial cells, and 
desmin-positive hepatic stellate cells, as well as HMGB1 expression 
in other organs (Supplemental Figure 2, A–F). I/R injury is not only 
involved in the pathophysiology of a wide range of diseases and in 
complications of organ transplantation (34), but also represents a 
prototypical setting in which DAMPs elicit detrimental effects (6). 
Hmgb1Δhep mice displayed a profound reduction of infiltrating neu-
trophils and inflammatory gene expression following hepatic I/R 
injury, whereas the initial injury, as demonstrated by similar serum 
ALT levels and necrosis area, was similar to that seen in Hmgb1fl/fl 
mice (Figure 2, B–D). Similar to our in vitro data, Hmgb1 ablation 
in hepatocytes selectively affected neutrophils without impacting 
the number of F4/80-positive macrophages in the liver (Figure 
2E). At later time points, the reduced inflammation translated into 
amelioration of liver injury (Figure 2, F and G), consistent with the 
notion that recruited neutrophils promote collateral damage and 
that HMGB1 is part of this neutrophil-mediated injury amplifica-
tion loop. To confirm the relevance of HMGB1 as a disease-pro-
moting DAMP in a second clinically relevant disease setting, we 
subjected Hmgb1Δhep and Hmgb1fl/fl mice to acetaminophen-induced 
liver injury. Acetaminophen intoxication induces HMGB1 release 
in mice (Supplemental Figure 3A) and humans (35) and represents 
the most common cause of acute liver failure in patients (36), with 
70,000 annual hospital visits in the US alone (37). Similar to our 
findings in hepatic I/R injury, the initial acetaminophen-induced 
liver injury was similar between Hmgb1Δhep and Hmgb1fl/fl mice (Fig-
ure 3A). Despite this similar initial injury, we observed a strong 
reduction of early and late hepatic neutrophil infiltration and of 
Figure 1. HMGB1 does not mediate LPS-induced inflammation and lethality. Hmgb1fl/fl Mx1-Creneg and Hmgb1fl/fl Mx1-Crepos mice (Hmgb1del) (A–D) as well as 
Hmgb1fl/fl Vav1-Creneg and Hmgb1fl/fl Vav1-Crepos mice (Hmgb1ΔBM) (E and F) were treated with a lethal dose of LPS (80 mg/kg i.v.). (A–C) HMGB1 serum levels 
(A) (n = 4 per group), hepatic inflammatory gene expression (B), and serum chemokine levels (C) were determined in Hmgb1fl/fl and Hmgb1del (n = 7 per group) 
mice by ELISA and qPCR, respectively. (D) Survival was determined in Hmgb1fl/fl and Hmgb1del (n = 18 per group) mice. (E and F) Hmgb1fl/fl and Hmgb1ΔBM mice 
were treated with LPS (30 mg/kg). HMGB1 serum levels were determined 18 hours after LPS challenge (E) (n = 4 per group). Survival was determined in  
Hmgb1fl/fl and Hmgb1ΔBM mice (n = 12 per group). (G) Hmgb1fl/fl and Hmgb1ΔBM mice were treated with LPS (80 mg/kg). Survival was determined in Hmgb1fl/fl  
(n = 15) and Hmgb1ΔBM mice (n = 10). *P < 0.05, **P < 0.01, and ***P < 0.001 by 1-way ANOVA followed by Tukey’s multiple comparisons test (A, C, and E), 
unpaired 2-tailed t test (B), and  Mantel-Cox log-rank test (D, F, and G), respectively. Un, untreated; ND, nondetectable; NS, nonsignificant.
Downloaded from http://www.jci.org on February 13, 2015.   http://dx.doi.org/10.1172/JCI76887
The Journal of Clinical Investigation R e s e a R c h  a R t i c l e
5 4 2 jci.org   Volume 125   Number 2   February 2015
ated apoptotic liver injury (Figure 4, A–J), consistent with the 
notion that apoptosis is considered a low-inflammatory form of 
cell death (3). The unaltered hepatocyte injury in apoptotic injury 
models further corroborates our finding that HMGB1 status does 
not affect the intrinsic sensitivity of hepatocytes to cell death, 
thus emphasizing the cell-extrinsic nature of HMGB1-mediated 
inflammation in necrotic injury models.
HMGB1 from different cellular compartments differentially affects 
the inflammatory response after necrosis and exhibits distinct post-
translational modifications. The contribution of HMGB1 from dif-
ophen versus only 22% of Hmgb1fl/fl mice (Figure 3I). Despite slight 
differences in kinetics, these data strikingly resemble our findings 
in the I/R model, confirming HMGB1 as a bona fide DAMP and a 
key trigger of an inflammation-mediated injury amplification loop.
HMGB1 does not promote sterile inflammation or injury ampli-
fication after apoptosis. To determine whether HMGB1 mediates 
inflammatory responses to all forms of cell death, we next tested 
its role in TNF- and FAS-mediated apoptosis. In striking contrast 
to our findings in necrotic injury, hepatic HMGB1 deficiency did 
not alter inflammation, injury, or survival in FAS- or TNF-medi-
Figure 2. HMGB1 promotes neutrophil recruitment in vitro and in vivo. (A) Neutrophil and macrophage migration toward Hmgb1-floxed and Hmgb1- 
deleted (Hmgb1del) liver extracts (induced by Mx1-Cre), determined in Boyden chambers (left 2 panels, n = 3 per group, with representative results from 3 
separate isolations). Insert shows immunoblot confirming Hmgb1 deletion. Peritoneal inflammatory cell accumulation after i.p. injection of lysates from 
Hmgb1fl/fl (n = 7) and Hmgb1del (n = 8) livers. (B–E) Hmgb1fl/fl (n = 8) and Hmgb1Δhep (n = 9) mice were subjected to warm hepatic I/R and sacrificed 6 hours 
later. H&E staining (B, left panel) and serum ALT (B, right panel) demonstrate similar initial injury, whereas hepatic neutrophil infiltration (C) and hepatic 
expression of inflammatory genes (D) differed. Numbers of hepatic macrophages determined by F4/80 staining and staining with pan-macrophage 
antibody in Hmgb1fl/fl (n = 8) and Hmgb1Δhep (n = 9) mice (E). (F and G) Hepatic injury 24 hours after I/R injury in Hmgb1fl/fl (n = 11) and Hmgb1Δhep (n = 10) 
mice, determined by H&E staining (F) and serum ALT (G). *P < 0.05 and **P < 0.01 by 1-way ANOVA followed by Tukey’s multiple comparisons test (A) and 
unpaired 2-tailed t test (B–G). Scale bars: 200 μm.
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isoforms of HMGB1 in Hmgb1fl/fl mice, all in high abundance, with 
molecular weights of 25,469 Da and 24,587 Da (fully reduced 
HMGB1) and 25,467 Da and 24,585 Da (disulfide HMGB1) — all 
of these isoforms being either nonacetylated or acetylated at the 
2 NLS sites (ref. 40 and Supplemental Figure 6). One important 
difference between the Hmgb1Δhep and Hmgb1ΔBM mice was the com-
plete absence of disulfide HMGB1 in the Hmgb1Δhep mice (Supple-
mental Figure 6). Since both Hmgb1Δhep and Hmgb1ΔBM mice lacked 
detectable circulating acetylated HMGB1 (Supplemental Figure 
6), it can be concluded that acetylation alone is not sufficient to 
trigger neutrophil infiltration and that formation of disulphide 
HMGB1 in epithelial cells is likely crucial for this process.
HMGB1 promotes necrosis-induced sterile inflammation through 
RAGE. Having established epithelial HMGB1 as a disease-pro-
moting DAMP in clinically relevant settings, we next aimed to 
identify the receptor through which HMGB1 recruits neutrophils 
ferent cellular sources, such as dying epithelial cells and HMGB1- 
secreting inflammatory cells, remains only poorly understood (4, 
38). To investigate whether HMGB1 from BM-derived cells affects 
injury responses in addition to the observed role of epithelial 
HMGB1, we used the above-described Vav1-Cre–deleted Hmgb1ΔBM 
mice. In contrast to Hmgb1Δhep mice, Hmgb1ΔBM mice did not dis-
play altered hepatic neutrophil infiltration, inflammatory gene 
expression, or liver injury following necrosis (Supplemental Fig-
ure 5, A–D), thus emphasizing the key role of epithelial HMGB1 in 
triggering injury responses following necrotic cell death. In light 
of recent reports indicating that posttranslational modifications of 
HMGB1 modulate its bioactivity, we used proteomic mass spec-
trometry (MS) and tandem mass spectrometry (MS/MS) (39) to 
identify the presence of HMGB1 posttranslational modifications 
in the serum of acetaminophen-treated mice and to assign them 
to specific cellular sources. We observed the presence of 4 distinct 
Figure 3. HMGB1 mediates neutrophil recruitment, injury amplification, and lethality following acetaminophen-induced liver necrosis. (A) Serum ALT 
and liver histology in Hmgb1fl/fl (n = 8) and Hmgb1Δhep (n = 7) mice 3 hours after injection of acetaminophen (300 mg/kg). (B) Acetaminophen-induced death 
in Hmgb1fl/fl and Hmgb1Δhep hepatocytes (n = 3 separate isolations per group). (C–H) Hepatic neutrophil recruitment (C), inflammatory gene expression (D), 
macrophage numbers (E and F), serum ALT and AST (G), and liver necrosis (H) 24 hours after acetaminophen (300 mg/kg) injection in Hmgb1fl/fl (n = 8) and 
Hmgb1Δhep (n = 8) mice. (I) Survival after a lethal dose of acetaminophen (500 mg/kg) in Hmgb1fl/fl and Hmgb1Δhep (n = 13 per group) mice. *P < 0.05,  
**P < 0.01, and ***P < 0.001 by 2-tailed unpaired t test (A–H) and Mantel-Cox log-rank test (I). Scale bars: 200 μm (A, C, E, and H) and 100 μm (B).
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and amplifies injury in vivo, focusing on Toll-like receptor 4 
(TLR4) and the receptor for advanced glycation end-products 
(RAGE) as the best-established HMGB1 receptors (41). Whereas 
TLR4-deficient neutrophils displayed normal migration toward 
liver lysates, migration of RAGE-deficient neutrophils toward 
liver lysates, but not toward our positive control GM-CSF, was 
reduced by 80% (Figure 5A). To confirm these results in vivo 
and to test whether RAGE deficiency affects injury responses in 
a manner similar to that of HMGB1 ablation, we subjected WT, 
TLR4-deficient, and RAGE-deficient mice to a sublethal dose of 
acetaminophen. In line with the above in vitro findings, we did 
not detect differences in neutrophil infiltration, inflammation, 
or liver injury between WT and TLR4-deficient mice (Figure 
5, B–E), but noted a profound reduction of these parameters in 
RAGE-deficient mice, similar to that observed in Hmgb1-deleted 
mice (Figure 5, F–I). Like Hmgb1Δhep hepatocytes, RAGE-deficient 
hepatocytes displayed normal acetaminophen metabolization 
and preserved sensitivity to acetaminophen-induced cell death 
(Supplemental Figure 7, A–C). To substantiate the hypothesis 
that RAGE expressed on BM-derived inflammatory cells and not 
other RAGE-expressing cell types is responsible for neutrophil 
infiltration, inflammation, and injury in response to necrosis, we 
generated RAGE BM–chimeric mice (Supplemental Figure 8, A 
and B). Following a sublethal dose of acetaminophen, chimeric 
mice with RAGE-deficient BM displayed strongly reduced neu-
trophil infiltration, inflammation, and late liver injury (Figure 6, 
A–D), similar to that seen in mice with global RAGE deficiency. 
Of note, macrophage depletion did not affect hepatic neutrophil 
recruitment after acetaminophen treatment (Supplemental Fig-
ure 9), confirming that the HMGB1-triggered neutrophil infil-
tration into the liver was not an indirect effect through RAGE-
expressing macrophages. These findings are consistent with 
our observation that necrotic tissue could directly stimulate the 
migration of RAGE-expressing, but not RAGE-deficient, neu-
trophils in vitro (Figure 5A).
HMGB1-recruited neutrophils amplify injury following necrosis.  
To directly link neutrophil infiltration to amplification of liver 
injury, we investigated whether inhibition of neutrophil function 
ameliorates acetaminophen-induced injury. We tested the role 
of neutrophils in injury amplification using chimeric mice with 
Figure 4. HMGB1 does not modulate inflammation, injury, or survival in response to FAS- or TNF-induced apoptosis. (A and B) Hepatic inflammatory 
gene expression (A) and neutrophil infiltration (B) 10 hours after injection of a sublethal dose of the FAS-agonistic antibody Jo2 (0.15 μg/g) in Hmgb1fl/fl  
(n = 6) and Hmgb1Δhep (n = 7) mice. (C) Hepatic H&E staining and hemorrhage 5 hours after a lethal dose of Jo2 (0.5 μg/g) in Hmgb1fl/fl and Hmgb1Δhep (n = 3 
per group) mice. (D and E) Serum ALT after 5 hours (D) and survival (E) in Hmgb1fl/fl (n = 9) and Hmgb1Δhep (n = 10) mice after Jo2 injection (0.5 μg/g). (F–J) 
Mice were injected with 700 μg/kg D-Gal and 100 μg/kg LPS. Hepatic inflammatory gene expression (F), neutrophil infiltration (G), hemorrhage (H), and 
serum ALT (I) 6 hours later in Hmgb1fl/fl and Hmgb1Δhep (n = 5 per group) mice. (J) Survival of Hmgb1fl/fl and Hmgb1Δhep (n = 10 per group) mice. Statistical 
significance assessed by 2-tailed unpaired t test (A–D and F–I) and Mantel-Cox log-rank test (E and J). Scale bars: 200 μm (B, C, G, and H).
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BM-specific deficiency of neutrophil elastase (Elane), a protease 
that is essential for neutrophil effector functions but not for neu-
trophil migration (42). Mice with Elane–/– BM displayed profoundly 
reduced necrosis and ALT levels after acetaminophen challenge 
despite intact hepatic neutrophil recruitment (Figure 6, E–I), 
thus confirming that neutrophils in injured tissue amplify already 
existing injury. To further determine whether this HMGB1-depen-
dent neutrophil-mediated injury amplification pathway could be 
pharmacologically exploited, we tested the effects of the HMGB1 
inhibitor glycyrrhizin (12, 43). This inhibitor is a natural compo-
nent of liquorice and has been widely used for the treatment of 
liver disease in Asia and Europe (44), but its mechanisms of action 
are not understood. Glycyrrhizin markedly attenuated acetamin-
ophen-induced hepatic inflammation and injury (Supplemen-
tal Figure 10, A–C) to almost the same degree as that of genetic 
HMGB1 ablation. Moreover, treatment with glycyrrhizin 2 hours 
after acetaminophen intoxication also reduced liver injury, albeit 
to a lesser extent than did pretreatment (Supplemental Figure 10, 
D and E), suggesting the possibility of pharmacologic prevention 
of HMGB1-mediated injury amplification.
Discussion
Using conditional HMGB1 ablation, our study could for the first 
time to our knowledge reliably characterize the contributory 
role of HMGB1 to inflammatory processes driven by LPS and 
necrosis, the 2 proposed key functions of HMGB1. Surprisingly, 
our results revealed no role of HMGB1 in the promotion of LPS- 
induced lethal shock. Although we cannot fully explain differences 
in a previous study by Tracey et al., which demonstrated a 70% 
reduction of lethality by HMGB1-neutralizing antibodies (13), 
our approach virtually eliminated LPS-induced serum HMGB1 
by 2 genetic approaches and therefore effectively rules out a key 
role of HMGB1 in promoting LPS-induced lethality. Similar dif-
ferences between pharmacologic and genetic approaches have 
Figure 5. RAGE, but not TLR4, mediates neutrophil recruitment following necrosis. (A) Migration of WT, Tlr4–/–, and RAGE-deficient (RAGE encoded 
by Ager) neutrophils (Ager–/– neutrophils, n ≥2 separate isolations per experiment) toward WT liver lysates. GM-CSF served as a positive control. (B–E) 
Analysis of hepatic neutrophil infiltration (B), inflammatory gene expression (C), H&E staining and necrosis quantification (D), and serum ALT concentra-
tions (E) in WT (n = 9) and Tlr4–/– (n = 7) mice treated with acetaminophen (300 mg/kg). (F–I) Analysis of hepatic neutrophil infiltration (F), inflammatory 
gene expression (G), H&E staining and necrosis quantification (H), and serum ALT concentrations (I) in WT (n = 10) and Ager–/– (n = 9) mice treated with 
acetaminophen (300 mg/kg). *P < 0.05 and **P < 0.01 by unpaired 2-tailed t test. Scale bars: 200 μm.
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migration of human neutrophils toward necrotic tissue (Supple-
mental Figure 11), our results suggest that HMGB1 might serve as 
a therapeutic target for diseases in which cell death is a key disease 
driver. Our post-treatment data for glycyrrhizin also suggest that 
targeting HMGB1 may have to be a truly preventive approach, i.e., 
before cell death occurs (e.g., as treatment in chronic diseases) 
or given at very early time points before HMGB1-induced neu-
trophil recruitment has started. In contrast to the striking effects 
of epithelial HMGB1 ablation, we observed no contribution of 
HMGB1 in BM-derived cells following necrosis, suggesting that 
HMGB1 fulfills other functions in this compartment. Our results 
also underpin the notion that DAMPs such as HMGB1 are critical 
in response to necrosis but not apoptosis — as HMGB1 ablation did 
not alter TNF- or FAS-induced injury responses or lethality.
Our study further highlights the role of RAGE as the receptor 
target for HMGB1, promoting neutrophil migration to necrotic tis-
sue. We observed the requirement of RAGE not only in neutrophil 
migration toward necrotic tissue in vitro, but also in the acet-
aminophen model in vivo. The contribution of RAGE on non–BM- 
derived cell populations to acetaminophen-induced neutrophil 
migration was excluded using BM-chimeric mice. Likewise, we did 
not observe a role for TLR4, another receptor target of HMGB1, 
in inflammatory responses to necrotic injury, nor in the migration 
been observed in studies of TNF in septic shock in mice (21–27), 
and subsequent studies in humans have failed to reproduce 
therapeutic effects of TNF neutralization seen in mice (28). A 
recent study by Yanai et al., using conditional ablation of HMGB1 
exons 2–4 in myeloid cells also reported no protection from LPS- 
induced lethality by Hmgb1 deletion (18). However, in contrast to 
our study, Yanai et al. reported only marginally lowered levels of 
serum HMGB1 levels, thus precluding conclusions about the func-
tional contribution of extracellular HMGB1 to LPS-induced shock 
(18). In our study, there was even a trend toward slightly increased 
LPS-induced lethality in mice with Mx1-Cre–mediated Hmgb1 
deletion, but not in mice with Vav1-Cre–mediated deletion (at 2 dif-
ferent doses), indicating a possible but only minor role for HMGB1 
in protection from LPS-mediated septic shock, as suggested by 
Yanai et al. (18). Rather than being a key mediator of LPS-medi-
ated lethality, our study instead suggests that HMGB1 functions 
as a neutrophil-recruiting DAMP following necrosis. Its key role 
in controlling neutrophil infiltration and inflammation following 
necrosis was observed in 2 clinically relevant necrosis models and 
was further highlighted by the complete prevention of acetamin-
ophen-induced lethality in Hmgb1Δhep mice. In conjunction with 
the strong reduction of inflammation and injury by the HMGB1 
inhibitor glycyrrhizin and a key role of HMGB1 in promoting the 
Figure 6. RAGE-expressing neutrophils promote injury amplification after necrotic injury. (A–D) Neutrophil infiltration (A), inflammatory gene 
expression (B), H&E staining and necrosis (C), and serum ALT concentrations (D) in chimeric mice with WT BM (n = 8) and Ager–/– BM (n = 10) treated with 
acetaminophen (300 mg/kg). (E–I) Chimeric mice with WT BM and Elane–/– BM (n = 12 per group) were treated with acetaminophen (300 mg/kg). Hepatic 
neutrophil infiltration was determined by staining for Ly6-B (E). BM reconstitution was confirmed by qPCR for Elane in spleens of BM-chimeric mice (F). 
Hepatic inflammatory gene expression was determined by qPCR (G). Liver injury was assessed by hepatic H&E staining and necrosis quantification (H), 
and serum ALT concentrations (I). *P < 0.05 and **P < 0.01 by unpaired 2-tailed t test. Scale bars: 200 μm.
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ened hepatic injury, even at early time points after I/R, as well as 
in worsened pancreatitis (17, 49). Of note, the targeting strategy in 
these studies appears to affect mitochondrial quality and function, 
which are likely to affect the injury response (17, 49), whereas our 
approach avoids this potential confounder (16). Our data indicate 
that HMGB1 isoforms differ between epithelial cells and BM- 
derived cells and suggest disulfide HMGB1 as a key mediator 
whose absence in epithelial cells is correlated with reduced neu-
trophil recruitment and injury. While our data demonstrate the 
hepatocyte-specific origin of disulfide HMGB1 following injury, it 
is also conceivable that HMGB1 oxidation to its disulfide isoform 
within hepatocytes requires hepatic recruitment of neutrophils, 
a key source of ROS. Importantly, disulfide HMGB1 has recently 
been shown to exert cytokine-like properties, whereas all-thiol 
HMGB1 exerts chemotactic activity via CXCL12 heterodimeriza-
tion and CXCR4 activation (20). Since the chemotactic activity 
of HMGB1-containing liver extracts toward neutrophils was not 
mediated via CXCR4, it needs to be investigated whether fully 
reduced HMGB1 (which was present in Hmgb1Δhep mice, albeit at 
reduced levels) or disulfide HMGB1 (which was absent in Hmgb1Δhep 
mice) mediates this chemotactic activity in neutrophils.
While our study characterized the role of the HMGB1/RAGE 
axis using the liver as a model system, in which necrotic injury is 
accompanied by massive neutrophil infiltration and often results in 
life-threatening acute liver failure, we did not study its contribution 
to disease processes in other organs or in other contexts. Our data 
showing reduced neutrophil migration toward HMGB1-deleted 
cardiac tissue lysates (Supplemental Figure 12) suggest, in principle, 
that the neutrophil-recruiting HMGB1/RAGE axis may be opera-
tional in other tissues. Since other DAMPs such as formyl-peptides 
and SAP130 and their corresponding receptors (FPR-1 and Mincle, 
respectively) may mediate neutrophil recruitment in settings such 
as heat-induced liver injury (50) or irradiation-induced thymocyte 
death (51), the relative contribution of specific DAMPs needs to be 
further studied and compared between different injury types and 
organs. Moreover, the role of HMGB1 released from immune cells, 
e.g., undergoing pyroptosis or NETosis during infection, is likely to 
differ substantially from HMGB1 released during necrosis (52). In 
this regard, the benefits of HMGB1-mediated neutrophil recruit-
ment in sterile inflammation and LPS-induced shock need to be 
better understood. It could be speculated that HMGB1 recruits 
neutrophils not only to promote phagocytosis of cellular debris, but 
also to constitute a preemptive strike against secondary infection 
of necrotic tissue — at the price of increased tissue injury. Likewise, 
the increase in HMGB1 secretion after LPS — rather than mediat-
ing lethal complications of LPS — may be involved in recruiting or 
activating effector cells in order to fight bacterial infections, as was 
recently suggested by Yanai et al. (18). Finally, cell death is a key 
driver of many disease processes including cancer, suggesting that 
DAMPs such as HMGB1 provide a link between epithelial injury 
and cancer in the setting of chronic injury.
Methods
Animals. Mice were maintained on a 12-hour dark/12-hour light cycle 
with free access to food and water unless otherwise indicated. Six- to 
8-week-old mice were used for all experiments. Hmgb1fl/fl mice and 
MHC-Cre mice have been previously described (16). C57BL6 mice, 
of neutrophils toward necrotic tissue in vitro. Although liver-resi-
dent macrophages typically do not increase following liver injury, 
BM-derived macrophages often migrate to sites of injury (45). 
However, we did not observe effects of epithelial Hmgb1 deletion 
on macrophage migration in vitro, nor on the number of hepatic 
macrophages in vivo, suggesting that the HMGB1/RAGE axis 
selectively modulates neutrophil migration toward injured tissue. 
Moreover, our in vitro migration assays and in vivo data, includ-
ing experiments in which mice were depleted of macrophages, 
demonstrate that the HMGB1/RAGE axis provides a direct link 
between necrotic cells and neutrophils without requirement for 
macrophage-mediated signals. Using Elane–/– BM–chimeric mice, 
our study firmly established injury amplification by HMGB1- 
recruited neutrophils. Our study focused primarily on pathways 
through which necrotic tissue triggers neutrophil recruitment 
and sterile inflammation and did not determine in detail effector 
pathways through which neutrophils amplify tissue injury. The 
incomplete inhibition of liver injury in mice lacking Elane is con-
sistent with previous studies that demonstrate the essential role of 
additional pathways such as proteinase 3 in neutrophil activation 
(46). Moreover, recent studies have also highlighted the role of 
additional DAMP receptors such as CLEC12A in the negative reg-
ulation of inflammation in response to cell death responses (47), 
suggesting that these may counteract the proinflammatory effects 
of HMGB1. Future studies need to further investigate the func-
tional interactions between pro- and antiinflammatory DAMP 
receptors on neutrophils following necrosis and determine the 
effectors through which HMGB1-recruited neutrophils exacerbate 
tissue injury. These are likely to not only include neutrophil pro-
teases and ROS, but possibly also neutrophil extracellular traps, a 
key effector of neutrophils in infection (48).
Before being known as a DAMP, HMGB1 was described as a 
nuclear protein with intracellular functions, such as bending of 
DNA, to facilitate DNA-protein interactions (14). We previously 
did not find evidence for a requirement of intracellular HMGB1 
in the regulation of gene expression, organ function, and viability 
after tissue-specific ablation of exons 2–4 of Hmgb1 (16), consis-
tent with the lack of a spontaneous phenotype in mice with condi-
tional HMGB1 ablation from other groups (17, 18). Our results indi-
cate that intracellular functions of HMGB1 are likely restricted to 
development and/or specific cell types and that the main function 
of HMGB1 in epithelial cells lies in its role as a danger signal in 
the extracellular space in the context of tissue injury. Consistent 
with these findings, we also do not observe a role of intracellular 
HMGB1 in epithelial injury responses: (a) in our 2 necrosis mod-
els, initial injury of epithelial cells is similar and only diverges at 
later time points after differences in inflammation and neutrophil 
infiltration have occurred; (b) in the acetaminophen models, we 
found APAP metabolization and similar APAP-induced death of 
primary hepatocytes in floxed and Hmgb1-deleted mice; (c) the 
sensitivity to FAS- and TNF-induced injury was not altered by 
HMGB1 status. Consistent with these findings, Yanai et al. found 
no effect of Hmgb1 deletion on early liver injury after hepatic I/R 
(18). However, their study did not further investigate DAMP func-
tions of HMGB1, such as neutrophil infiltration, inflammation, 
and late liver injury (18). In contrast to our study and that of Yanai 
et al., conditional ablation of HMGB1 exons 2–3 resulted in wors-
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Chemotaxis assays. To assess the effects of HMGB1 on neutrophil 
migration toward necrotic tissue, HMGB1-containing and HMGB1- 
deficient liver extracts were prepared according the following procedure: 
Hmgb1fl/fl Mx1-Cre–positive and Mx1-Cre–negative mice were injected 
3 times with poly-(I:C), and livers were harvested 10 days later. Livers 
were lysed in sterile PMN buffer (PBS containing glucose and BSA) and 
subjected to 5 freeze-thaw cycles, followed by centrifugation. For in vitro 
chemotaxis assays, neutrophils were isolated from the peripheral blood 
of healthy donors using a histopaque gradient as previously described 
(56). For additional experiments involving WT and Ager–/– neutrophils, 
neutrophils were isolated from the BM of WT or Ager–/– mice as previously 
described (57). For some experiments, neutrophils and liver extracts 
were pretreated with either the CXCR4 inhibitor AMD3100 (Sigma- 
Aldrich) or anti–mouse CXCL2 antibody (AF-452-NA; R&D Systems). 
Neutrophil chemotaxis through 3-μm inserts (BD) coated with laminin, 
fibronectin, or fibrinogen was determined in Boyden chambers, with 1 × 
106 neutrophils placed in the upper chamber and 30 mg liver extract in 
the lower chamber, both in sterile PMN buffer. Migration was quantified 
after 3 hours. Chemotaxis of macrophages was performed in an analo-
gous manner using BM-derived macrophages, isolated as previously 
described (58), using 8-μm-pore-size filters. For in vivo chemotaxis, 30 
mg lysed liver tissue was injected i.p. into recipient mice. After 20 hours, 
the peritoneum of the recipient mice was lavaged with 4 ml sterile PBS, 
and cells were counted using a hemocytometer.
RNA extraction, qPCR, Western blotting, and immunohistochemistry. 
RNA from snap-frozen tissues was column purified (Roche Diagnos-
tics). Following reverse transcription, qPCR was performed as previ-
ously described using primer-probe pairs (Applied Biosystems), with 
normalization to 18S and relative quantification by the standard curve 
method (59). Electrophoresis of protein extracts and subsequent blot-
ting were performed as previously described (54). Blots were incubated 
with rabbit antibody against HMGB1 at a dilution of 1:1,000 (ab18256; 
Abcam) and rabbit anti–acetaminophen protein adducts (a gift of L. 
Pohl, NIH, Bethesda, Maryland, USA) at a dilution of 1:1,000 to 1:5,000 
and visualized by chemiluminescence (Thermo Scientific). Blots were 
reprobed with mouse antibodies against β-actin (A5441; Sigma-Aldrich) 
or GADPH (G9225; Sigma-Aldrich). Immunohistochemical staining 
was performed on paraffin-embedded liver sections after 10% forma-
lin fixation using a primary antibody against Ly-6B.2 (clone MCA771G; 
AbD Serotec) and anti-F4/80 (clone CI:A3-1, catalog MCA497R; AbD 
Serotec), followed by biotinylated anti–rabbit or anti–rat IgG, respec-
tively, and developed with DAB peroxidase substrate (Vector Labora-
tories). HMGB1 immunohistochemistry was performed using rabbit 
anti–HMGB1 (ab18256; Abcam). To identify HMGB1 in specific cell 
populations, hepatocytes were identified by HNF4α staining (using anti-
HNF4α antibody SC-6556; Santa Cruz Biotechnology Inc.), hepatic stel-
late cells by desmin staining (using Thermo Scientific Lab Vision anti–
desmin RB-9014-P antibody), macrophages (using clone CI:A3-1 from 
AbD Serotec for F4/80 or pan-macrophage antibody ab56297 from 
Abcam), endothelial cells by endomucin staining (using anti-endomu-
cin antibody sc-65495; Santa Cruz Biotechnology Inc.), and by fluores-
cent secondary antibodies as previously described (60), followed by 
confocal microscopy on a Nikon A1R MP confocal microscope (Nikon 
Instruments) with a ×40 oil immersion lens.
Hepatocyte isolation. Mouse hepatocytes were isolated as previ-
ously described via 2-step collagenase perfusion (59). Hepatocytes 
were allowed to attach for 90 minutes on collagen-coated plates in 
albumin-Cre mice, Mx1-Cre mice, Vav1-Cre mice, and TLR4-knockout 
mice were obtained from The Jackson Laboratory. RAGE-knockout 
mice were a gift of Ann-Marie Schmidt (New York University, New 
York, New York, USA). Mx1-Cre activation for deletion of Hmgb1 was 
induced by 3 i.p. injections of poly(I:C) (10 mg/kg; GE Healthcare), 
given every other day (30).
Models of LPS-induced inflammation and mortality. Four weeks 
after administration of poly-(I:C), Hmgb1fl/fl and Hmgb1del mice were 
injected i.v. with LPS (80 mg/kg) dissolved in saline to induce systemic 
inflammation and lethal shock. Serum was collected after 3 and 18 
hours to determine HMGB1 serum levels by ELISA (IBL International). 
For some experiments, mice were sacrificed after 18 hours to collect 
tissue. For survival analysis, animals were injected with 80 mg/kg 
LPS and monitored without further manipulation. To determine 
the contribution of HMGB1 from BM-derived cells, Vav1-Cre–nega-
tive Hmgb1fl/fl and Vav1-Cre–positive Hmgb1fl/fl mice (Hmgb1ΔBM) were 
treated accordingly, without prior exposure to poly-(I:C).
Liver injury models. Mice were injected i.v. with hamster anti–
mouse anti–CD95 antibody (10 μg/mouse, clone Jo2, catalog 554254; 
BD Biosciences) or with 700 μg/kg D-galactosamine i.p. followed by 
100 μg/kg LPS i.v. (both from Sigma-Aldrich) 2 hours later. Mice were 
sacrificed 4 hours after the LPS injection or monitored for survival. 
Acetaminophen intoxication was induced in overnight-starved male 
mice by i.p. injection of 300 mg/kg (sublethal dose) or 500 mg/kg 
(lethal dose) acetaminophen (Sigma-Aldrich), dissolved in sterile 
warm saline. For some experiments, mice were pretreated with either 
clondroate liposomes or PBS liposomes (200 μl/mouse, obtained 
from Nico van Rooijen, Vrije Universiteit, Amsterdam, The Nether-
lands), followed by treatment with acetaminophen 96 hours later. For 
some experiments, mice were pretreated with 50 mg/kg glycyrrhizic 
acid dissolved in saline (catalog 50531; Sigma-Aldrich). For ischemia/
reperfusion experiments, male mice were starved overnight and sub-
jected to warm partial hepatic ischemia as previously described (53). 
Briefly, after midline abdominal incision, the liver hilum was exposed, 
and the hepatic artery, portal vein, and bile duct were occluded using 
a microvascular clamp (Fine Science Tools) proximally to caudate 
hepatic branches to avoid portal venous congestion. Rapid blanching 
of the respective liver lobes indicated ischemia. Body temperature 
was monitored with a UV thermometer (Fisher Scientific) and main-
tained at 37°C ± 1°C with heat pads and warm lamps. After 60 minutes 
of ischemia, the clamp was removed, and reperfusion of all segments 
was visually confirmed. In the event of incomplete reperfusion, the 
animal was excluded from further analysis.
BM transplantation. BM transplantation (BMT) experiments were 
performed as previously described (54). Briefly, 5 × 106 BM cells from 
donor animals were injected i.v. into lethally irradiated (2 × 6 Gy) 
recipients. Successful BMT in RAGE chimeric mice was confirmed via 
GFP fluorescence as described (55), taking advantage of GFP expres-
sion in Ager–/– mice. Successful BMT in Elane chimeric mice was con-
firmed by quantitative PCR (qPCR) in spleens. APAP treatment was 
performed 8 weeks after BMT.
Serum transaminase, chemokine, and HMGB1 measurements. Serum 
ALT and AST measurements were performed using ALT/GPT and AST/
GOT kits (both from Thermo Scientific) according to the manufactur-
er’s instructions and calculated using a standard curve. IL-6 and MCP-1 
ELISA (both from R&D Systems) and HMGB1 ELISA (IBL Interna-
tional) were performed according to the manufacturer’s instructions.
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180 μm × 20 mm nanoACQUITY UPLC C18 trap column and a 75 μm × 
15 cm nanoACQUITY UPLC BEH130 C18 column (Waters) via reduc-
ing unions. A gradient from 0.05% TFA (v/v) to 50% ACN/0.08% 
TFA (v/v) over a 40-minute period was applied at a flow rate of 200 
nl/minute (63). The ion spray potential was set at 2,200 to 3,500 V, the 
nebulizer gas at 19, and the interface heater at 150°C.
Statistics. All data are expressed as the mean ± SEM. For comparison 
of 2 groups, an unpaired 2-tailed t or Mann-Whitney U test was used. 
Differences in survival were compared using a log-rank (Mantel-Cox) 
test. A P value of less than 0.05 was considered statistically significant.
Study approval. All animal procedures were performed with 
Columbia University IACUC approval and were in accordance with 
the Guide for the Care and Use of Laboratory Animals (National Acad-
emies Press. 8th edition. Revised 2011). Isolatio of neutrophils from 
the blood of volunteers was performed with Columbia University 
IRB approval.
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RPMI containing 10% FBS (Gibco), followed by overnight starvation 
in serum-free medium before experiments. Cells were harvested 
for protein analysis 3 hours after APAP exposure, and cell death was 
quantified by assessing the percentage of PI-positive nuclei 24 hours 
after APAP exposure.
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with 5 μg rabbit anti–HMGB1 (ab18256; Abcam) for 16 hours at 4°C as 
previously described (61). For the analysis of HMGB1 posttranslational 
modifications, free thiol groups within HMGB1 were alkylated for 90 
minutes with 10 mM iodoacetamide at 4°C. Cysteine residues in disul-
fide bonds were then reduced with 30 mM dithiothreitol at 4°C for 
1 hour followed by alkylation of newly exposed thiol groups with 90 mM 
NEM at 4°C for 10 minutes as previously described (62). Samples were 
subjected to trypsin (Promega) or GluC (New England BioLabs Inc.) 
digestion according to the manufacturer’s instructions and desalted 
using C18 Ziptips (EMD Millipore). Characterization of acetylated or 
phosphorylated lysine residues and redox modifications on cysteine 
residues within HMGB1 were determined using an AB SCIEX QTRAP 
5500 (AB SCIEX) equipped with a NanoSpray II source by in-line 
liquid chromatography using a U3000 HPLC System connected to a 
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